NCT05513001: An ongoing trial by Novartis Pharmaceuticals
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05513001 |
|---|---|
| Title | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 9, 2022 |
| Completion date | Aug. 26, 2024 |
| Required reporting date | Aug. 26, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |